Skip to main content

Table 4 Tests for Heterogeneity of Treatment Effect According to the Clinicopathological Characteristics of the D1 and D2 Patients.

From: Does D3 surgery offer a better survival outcome compared to D1 surgery for gastric cancer? A result based on a hospital population of two decades as taking D2 surgery for reference

Subgroup

D1 surgery

D2 surgery

HR (95% CI)

p

 

No. of deaths/no. of patients

  

Total

150/187

157/189

0.982(0.785-1.229)

 

Age (years)

    

   ≤55

49/66

88/107

0.877(0.618-1.244)

0.462

   >55

101/121

69/82

1.016(0.748-1.380)

0.919

Sex

    

   Women

41/51

40/52

1.308(0.843-2.029)

0.231

   Men

109/136

117/137

0.878(0.676-1.140)

0.329

Tumor size

    

   ≤5

91/125

97/121

0.921(0.692-1.227)

0.575

   5-7

30/32

34/40

1.178(0.714-1.941)

0.522

   >7

29/30

26/28

1.143(0.672-1.945)

0.622

Tumour site

    

   Upper stomach

40/44

32/39

1.205(0.752-1.930)

0.438

   Middle stomach

35/43

41/50

1.086(0.691-1.706)

0.721

   Lower stomach

64/88

72/87

0.806(0.575-1.130)

0.212

   Whole stomach

11/12

12/13

1.062(0.464-2.429)

0.887

Gross appearance

    

   Borrmann types I

37/58

45/55

0.618(0.399-0.958) †

0.031*

   Borrmann types II

33/41

31/44

1.189(0.727-1.945)

0.490

   Borrmann types III

66/73

66/74

1.327(0.938-1.878)

0.110

   Borrmann types IV

14/15

15/16

1.105(0.528-2.312)

0.791

Tumour stage

    

   T1

29/41

35/40

0.755(0.458-1.243)

0.269

   T2

30/44

32/45

1.093(0.661-1.808)

0.729

   T3

79/89

75/87

1.073(0.782-1.473)

0.662

   T4

12/13

15/17

0.854(0.383-1.906)

0.700

Clinical node status

    

   Negative

4/5

2/3

2.654(0.458-15.362)

0.276

   Positive

146/182

155/186

0.965(0.770-1.210)

0.759

Lymph-node stage

    

   N0

50/69

46/60

1.004(0.672-1.500)

0.984

   N1

64/75

80/93

1.040(0.748-1.446)

0.814

   N2

24/30

21/26

0.820(0.455-1.477)

0.508

   N3

12/13

10/10

0.376(0.153-0.922)†

0.033*

Histological type

    

   Differentiated

62/99

55/88

1.033(0.921-1.783)

0.136

   Undifferentiated

50/88

56/101

1.157(0.833-1.947)

0.390

Joint organ removal

    

   None

127/160

124/148

0.960(0.749-1.229)

0.745

   Pancreas or spleen

6/7

13/16

1.340(0.502-3.575)

0.559

   Liver or gall

9/11

4/8

2.959(0.796-10.992)

0.105

   Transverse colon

8/9

16/17

0.659(0.277-1.566)

0.345

Gastrectomy

    

   Total

20/22

20/21

1.089(0.583-2.036)

0.788

   Subtotal

130/165

137/168

0.970(0.763-1.233)

0.802

Blood transfusion

    

   No

63/87

70/85

0.900(0.640-1.265)

0.543

   Yes

87/100

87/104

1.056(0.785-1.422)

0.718

Blood loss

    

   ≤200

41/54

57/70

0.920(0.616-1.375)

0.685

   200-400

68/88

67/73

0.703(0.501-0.986) †

0.041*

   >400

41/45

33/46

1.870(1.175-2.977)

0.008*

  1. The P values are for hazard ratios for death in the group assigned to D1 lymphadenectomy and the group assigned to D2 lymphadenectomy, with 95% confidence intervals.
  2. The surgery is better for D1 lymphadenectomy when the HR is <1; and is better for D2 lymphadenectomy when the HR is >1.
  3. †Significantly better for D1 lymphadenectomy.
  4. *Considered significant.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us